Clinical evaluation of hepatocarcinogenesis and outcome using a novel glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) in chronic hepatitis C with advanced fibrosis.

This study aimed to assess the association between the serum glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) for liver fibrosis and outcomes and carcinogenesis (HCC) in chronic hepatitis C (CHC) patients with advanced fibrosis. Serum WFA+-M2BP levels were measured in 128 consecutive CHC patients including 49 HCC histopathologically diagnosed with advanced fibrosis (F3; 44, F4; 84) in our hospital. The median WFA+-M2BP level was significantly higher in F4 than F3 patients (6.9 vs 2.3 C.O.I., respectively; p<0.001). The difference in WFA+-M2BP levels between patients with/without HCC was not significant. The respective 5-/8-year survival rates of patients without HCC at enrollment with high (≥4 C.O.I., n=39), intermediate (1-4 C.O.I., n=33), and low WFA+-M2BP (<1 C.O.I., n=7) levels were 78%/48%, 100%/82% and 100%/100%, respectively. The differences in survival rates between groups were significant (p=0.0041). Patients with high WFA+-M2BP levels had a significantly higher incidence of HCC than those with low WFA+-M2BP levels (p=0.0019). Cumulative 5-year carcinogenesis rates in patients with high, intermediate, and low WFA+-M2BP levels were 48.7%, 16.9%, and 0%, respectively; the differences between groups were significant (p=0.002). Serum WFA+-M2BP levels might allow the prediction of carcinogenesis and outcome in CHC patients with advanced fibrosis. PMID: 29491234 [PubMed - as supplied by publisher]
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research